Committee Action
On February 14, 2024, the Subcommittee on Health held a
hearing on H.R. 7189. The title of the hearing was
``Legislative Proposals to Support Patients and Caregivers.''
The Subcommittee received testimony from:
Andy Shih, PhD, Chief Science Officer,
Autism Speaks;
Corey Feist, JD, MBA, Co-Founder and CEO,
Dr. Lorna Breen Heroes' Foundation;
Joanne Pike, DrPH, President and CEO,
Alzheimer's Association;
Gordon Tomaselli, MD, Former President,
American Heart Association; Marilyn and Stanley M. Katz
Dean, Emeritus and Professor of Medicine, Albert
Einstein College of Medicine; Adjunct Professor of
Medicine, Johns Hopkins University School of Medicine;
Michelle Whitten, President, CEO, and Co-
Founder, Global Down Syndrome Foundation;
Randy Strozyk, President, American Ambulance
Association; and
Christina Annunziata, MD, PhD, Senior Vice
President of Extramural Discovery Science, American
Cancer Society.
On March 12, 2024, the Subcommittee on Health met in open
markup session and forwarded H.R. 7189, as amended, to the full
Committee by a record vote of 24 yeas and 0 nays.
On March 20, 2024, the full Committee on Energy and
Commerce met in open markup session and ordered H.R. 7189, as
amended, favorably reported to the House by a record vote of 43
yeas and 0 nays.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to
continue to support efforts that improve scientific
understanding and public awareness of congenital heart disease.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 7189 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 7189:
On February 14, 2024, the Subcommittee on
Health held a hearing on H.R. 7189. The title of the
hearing was ``Legislative Proposals to Support Patients
and Caregivers.'' The Subcommittee received testimony
from:
Andy Shih, PhD, Chief Science
Officer, Autism Speaks;
Corey Feist, JD, MBA, Co-Founder
and CEO, Dr. Lorna Breen Heroes' Foundation;
Joanne Pike, DrPH, President and
CEO, Alzheimer's Association;
Gordon Tomaselli, MD, Former
President, American Heart Association; Marilyn
and Stanley M. Katz Dean, Emeritus and
Professor of Medicine, Albert Einstein College
of Medicine; Adjunct Professor of Medicine,
Johns Hopkins University School of Medicine;
Michelle Whitten, President,
CEO, and Co-Founder, Global Down Syndrome
Foundation;
Randy Strozyk, President,
American Ambulance Association; and
Christina Annunziata, MD, PhD,
Senior Vice President of Extramural Discovery
Science, American Cancer Society.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 7189 contains no earmarks, limited
tax benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides that the Act may be cited as the
``Congenital Heart Futures Reauthorization Act of 2024''.
Section 2. Reauthorization of national congenital heart disease
research, surveillance, and awareness program
Section 2 reauthorizes a national congenital heart disease
program. This section also requires the Secretary of Health and
Human Services (HHS) to issue a report to Congress within two
years of the bill's enactment. The report must include a
description and assessment of past and present activities at
HHS, as well as current CHD workforce capacity needs. In the
following year after report submission, a national strategy is
required to be submitted to Congress detailing efforts to
improve public awareness and train care providers on congenital
heart disease must be submitted as well.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
PUBLIC HEALTH SERVICE ACT
* * * * * * *
TITLE III--GENERAL POWERS AND DUTIES OF PUBLIC HEALTH SERVICE
* * * * * * *
PART P--ADDITIONAL PROGRAMS
* * * * * * *
SEC. 399V-2. NATIONAL CONGENITAL HEART DISEASE RESEARCH, SURVEILLANCE,
AND AWARENESS.
(a) In General.--The Secretary shall, as appropriate--
(1) enhance and expand research and data collection
efforts related to congenital heart disease, including
to study and track the epidemiology of congenital heart
disease to understand health outcomes for individuals
with congenital heart disease across all ages;
(2) conduct activities to improve public awareness
of, and education related to, congenital heart disease,
including care of individuals with such disease; and
(3) award grants to entities to undertake the
activities described in this section.
(b) Activities.--
(1) In general.--The Secretary shall carry out
activities, including, as appropriate, through a
national cohort study and a nationally-representative,
population-based surveillance system, to improve the
understanding of the epidemiology of congenital heart
disease in all age groups, with particular attention
to--
(A) the incidence and prevalence of
congenital heart disease in the United States;
(B) causation and risk factors associated
with, and natural history of, congenital heart
disease;
(C) health care utilization by individuals
with congenital heart disease;
(D) demographic factors associated with
congenital heart disease, such as age, race,
ethnicity, sex, and family history of
individuals who are diagnosed with the disease;
and
(E) evidence-based practices related to care
and treatment for individuals with congenital
heart disease.
(2) Permissible considerations.--In carrying out the
activities under this section, the Secretary may, as
appropriate--
(A) collect data on the health outcomes,
including behavioral and mental health
outcomes, of a diverse population of
individuals of all ages with congenital heart
disease, such that analysis of the outcomes
will inform evidence-based practices for
individuals with congenital heart disease; and
(B) consider health disparities among
individuals with congenital heart disease,
which may include the consideration of prenatal
exposures.
(c) Awareness Campaign.--The Secretary may carry out
awareness and educational activities related to congenital
heart disease in individuals of all ages, which may include
information for patients, family members, and health care
providers, on topics such as the prevalence of such disease,
the effect of such disease on individuals of all ages, and the
importance of long-term, specialized care for individuals with
such disease.
(d) Public Access.--The Secretary shall ensure that, subject
to subsection (e), information collected under this section is
made available, as appropriate, to the public, including
researchers.
(e) Patient Privacy.--The Secretary shall ensure that the
data and information collected under this section are made
available in a manner that, at a minimum, protects personal
privacy to the extent required by applicable Federal and State
law.
(f) Report and Strategy.--
(1) Report.--Not later than 2 years after the date of
enactment of the Congenital Heart Futures
Reauthorization Act of 2024, the Secretary shall issue
a report to the Committee on Energy and Commerce of the
House of Representatives and the Committee on Health,
Education, Labor, and Pensions of the Senate including
the following:
(A) A description of past and present
activities of the Department of Health and
Human Services to increase awareness and
knowledge of the public with respect to
congenital heart disease, including efforts to
address the lifelong needs of congenital heart
disease patients.
(B) An assessment of past and present
activities of the Department of Health and
Human Services to increase education and
training of health care providers with respect
to congenital heart disease, including efforts
to address the lifelong needs of congenital
heart disease patients.
(C) A description of the current workforce
capacity in the United States of health care
providers who treat adult patients living with
congenital heart disease.
(2) Strategy.--
(A) Development; submission to congress.--Not
later than 1 year after submitting the report
required by paragraph (1), the Secretary shall
develop and submit to Congress a strategy for
improving efforts to increase awareness and
knowledge of the public and education and
training of health care providers with respect
to congenital heart disease. Such strategy
shall include findings and recommendations to--
(i) address any public awareness and
research gaps and opportunities related
to the lifelong needs of congenital
heart disease patients, including long-
term health outcomes, quality of life,
mental health, and health care
utilization;
(ii) address any shortages in the
current workforce of health care
providers who treat adult patients
living with congenital heart disease,
which may include strategies to enhance
fellowship training programs or other
continuing education programs; and
(iii) foster collaboration and
dissemination of information across
Federal agencies, health care
providers, researchers, and patient
organizations.
(B) Consultation.--In developing the strategy
under subparagraph (A), the Secretary shall, as
appropriate, consult with qualified stakeholder
groups, including patient organizations, health
care professionals, research entities, health
insurance providers, accrediting organizations,
and relevant Federal agencies, including the
Centers for Disease Control and Prevention, the
National Institutes of Health, and the Health
Resources and Services Administration.
[(f)] (g) Eligibility for Grants.--To be eligible to receive
a grant under subsection (a)(3), an entity shall--
(1) be a public or private nonprofit entity with
specialized experience in congenital heart disease; and
(2) submit to the Secretary an application at such
time, in such manner, and containing such information
as the Secretary may require.
[(g)] (h) Authorization of Appropriations.--To carry out this
section, there are authorized to be appropriated $10,000,000
for each of fiscal years [2020 through 2024] 2025 through 2029.
* * * * * * *
[all]